NCT06282224 Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery
| NCT ID | NCT06282224 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Condition | Pituitary Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-01-22 |
| Primary Completion | 2025-01-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2024-01-22 with a primary completion date of 2025-01-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
"For lesions in the skull base, including meningiomas, chordomas and pituitary tumors, endoscopic surgery has replaced traditional microscopes as the mainstream procedure. Although neurosurgeons can enlarge the surgical area using a neuroendoscope, it does not provide any information on the morphology and location of anatomical structures beneath visible surfaces. Due to the complex anatomical relationships of adjacent structures in the skull base, lesions occurring here are often located deep within anatomy that is difficult to fully expose and remove with endoscopic surgery alone. Especially when dealing with larger tumors that surround major arteries and nerves, limited visibility at surface level can easily damage blood vessels or nerves causing complications such as bleeding during or after surgery, deformities or functional impairments. The purpose of this study is to explore how augmented reality (AR) technology can highlight important anatomical structures in a neuroendoscope's field of view to optimize surgical visibility beyond what is possible with just an endoscope alone. This will make it easier for surgeons to distinguish deeper anatomical structures and reduce intraoperative and postoperative complications associated with endoscopic surgery."
Eligibility Criteria
Inclusion Criteria： * Patients who are suitable for Transnasal endoscopic surgery 。 * Patients who have performed thin-layer head MRI and CTA scans before surgery. Exclusion Criteria： * Patients without clear preoperative imaging data. * Patients who do not agree to receive the assistance of AR fusion neuroendoscopy. * Patients with incomplete medical records.
Contact & Investigator
Hongwei Zhu, doctorate
STUDY DIRECTOR
The First Affiliated Hospital of Xiamen University
Frequently Asked Questions
Who can join the NCT06282224 clinical trial?
This trial is open to participants of all sexes, studying Pituitary Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06282224 currently recruiting?
Yes, NCT06282224 is actively recruiting participants. Contact the research team at haiwubians@163.com for enrollment information.
Where is the NCT06282224 trial being conducted?
This trial is being conducted at Xiamen, China.
Who is sponsoring the NCT06282224 clinical trial?
NCT06282224 is sponsored by The First Affiliated Hospital of Xiamen University. The principal investigator is Hongwei Zhu, doctorate at The First Affiliated Hospital of Xiamen University. The trial plans to enroll 10 participants.